ビジネス · 2020/7/171 分で読めます
Eli Lilly and Co.; Announcement of the Revocation of the Biologics License for LARTRUVO
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA or Agency) is announcing the revocation of the biologics license application (BLA) for LARTRUVO (olaratumab) injection. Eli Lilly and Co. requested withdrawal (revocation) of the biologics license application and has waived its opportunity for a hearing.